Idecabtagene vicleucel (ide-cel) versus standard regimens in patients with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): KarMMa-3, A phase III randomized controlled trial (RCT) Meeting Abstract
| Authors: | Giralt, S.; Ailawadhi, S.; Arnulf, B.; Patel, K.; Cavo, M.; Nooka, A. K.; Manier, S.; Callander, N.; Costa, L. J.; Vij, R.; Bahlis, N. J.; Moreau, P.; Solomon, S. R.; Delforge, M.; Berdeja, J.; Truppel-Hartmann, A.; Yang, Z.; Favre-Kontula, L.; Wu, F.; Piasecki, J.; Cook, M.; Rodríguez-Otero, P. |
| Abstract Title: | Idecabtagene vicleucel (ide-cel) versus standard regimens in patients with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): KarMMa-3, A phase III randomized controlled trial (RCT) |
| Meeting Title: | 11th Annual Meeting of the Society of Hematologic Oncology (SOHO 2023): Progress in Personalized Therapy |
| Keywords: | ct; progression-free survival; car t-cell therapy; idecabtagene vicleucel; relapsed and refractory multiple myeloma; phase iii randomized controlled trial |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 23 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Sep 6-9 |
| Meeting Location: | Houston, TX |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2023-09-01 |
| Start Page: | S527 |
| End Page: | S528 |
| Language: | English |
| ACCESSION: | WOS:001062479600641 |
| PROVIDER: | wos |
| DOI: | 10.1016/S2152-2650(23)01510-0 |
| Notes: | Meeting Abstract: CT-356 -- Source: Wos |
